DWTX
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Dogwood enrolls the first 200 patients in the Phase 2b Halneuron® trial for chemotherapy-induced neuropathy, with topline data expected in fall 2026Jul 21, 2026
- Dogwood Therapeutics initiated a long-term extension Phase 2b study of Halneuron for chemotherapy-induced neuropathic painMay 18, 2026
- Dogwood announces enrollment of first 100 patients in ongoing Halneuron® Phase 2b trial, interim sample size analysis on track for December 2025Nov 11, 2025